Association of accelerated switch from vertebral end‐plate Modic I to Modic 0 signal changes with clinical benefit of intradiscal corticosteroid injection for chronic low back pain

Modic I vertebral end‐plate signal changes detected by magnetic resonance imaging (MRI) are associated with chronic low back pain. Typically, Modic I signal changes in untreated patients switch to non–Modic I signal changes within 3 years, which reflect spontaneous healing. Recent findings suggest t...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 63; no. 9; pp. 2828 - 2831
Main Authors Nguyen, Christelle, Bénichou, Marc, Revel, Michel, Poiraudeau, Serge, Rannou, François
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2011
Wiley
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Modic I vertebral end‐plate signal changes detected by magnetic resonance imaging (MRI) are associated with chronic low back pain. Typically, Modic I signal changes in untreated patients switch to non–Modic I signal changes within 3 years, which reflect spontaneous healing. Recent findings suggest that Modic I signal changes may be related to local inflammatory changes, providing a rationale for treatment with intradiscal injections of antiinflammatory drugs. In the present report, we describe a 31‐year‐old man with 1‐year history of chronic low back pain associated with vertebral end‐plate Modic I signal changes, who received 1 intradiscal corticosteroid injection in L5–S1. Local treatment led to rapid pain relief and was associated with an accelerated switch from Modic I to Modic 0 signal changes, as seen on lumbar MRI at 1‐month followup. This is the first report of an effective local treatment for both the symptoms and the structural changes of chronic low back pain that are associated with Modic I signal changes. Additionally, this case reinforces the hypothesis that local inflammation has a pathogenic role.
Bibliography:Dr. Rannou has received consulting fees, speaking fees, and/or honoraria from Merck, Sharp, and Dohme, Expanscience, Genévrier, Rottapharm, and GlaxoSmithKline (less than $10,000 each).
Dr. Poiraudeau has received consulting fees, speaking fees, and/or honoraria from Sanofi Aventis, Pfizer, and Merck, Sharp, and Dohme (less than $10,000 each).
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0004-3591
2326-5191
1529-0131
2326-5205
DOI:10.1002/art.30443